William Lehmann, Jr. Sells 15,000 Shares of Athersys, Inc. (ATHX) Stock

Athersys, Inc. (NASDAQ:ATHX) insider William Lehmann, Jr. sold 15,000 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $1.53, for a total value of $22,950.00. Following the completion of the transaction, the insider now directly owns 468,751 shares of the company’s stock, valued at approximately $717,189.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Athersys stock opened at $1.55 on Wednesday. Athersys, Inc. has a 12 month low of $1.36 and a 12 month high of $3.09. The company has a market cap of $224.67 million, a P/E ratio of -8.61 and a beta of 0.49.

Athersys (NASDAQ:ATHX) last announced its quarterly earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Athersys had a negative return on equity of 49.25% and a negative net margin of 99.96%. The company had revenue of $1.51 million during the quarter, compared to analyst estimates of $0.55 million. On average, equities analysts anticipate that Athersys, Inc. will post -0.39 EPS for the current year.



A number of institutional investors have recently made changes to their positions in ATHX. Amalgamated Bank bought a new position in Athersys during the fourth quarter valued at approximately $25,000. Two Sigma Securities LLC bought a new position in Athersys during the fourth quarter valued at approximately $47,000. Marshall Wace LLP bought a new position in Athersys during the third quarter valued at approximately $59,000. Allred Capital Management LLC bought a new position in Athersys during the fourth quarter valued at approximately $74,000. Finally, Rhumbline Advisers boosted its stake in Athersys by 47.7% during the fourth quarter. Rhumbline Advisers now owns 144,257 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 46,565 shares during the last quarter. 20.45% of the stock is owned by institutional investors.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research raised Athersys from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Tuesday. ValuEngine raised Athersys from a “hold” rating to a “buy” rating in a research note on Friday, January 25th. Finally, Maxim Group set a $8.00 price objective on Athersys and gave the stock a “buy” rating in a research note on Wednesday, January 23rd.

ILLEGAL ACTIVITY WARNING: “William Lehmann, Jr. Sells 15,000 Shares of Athersys, Inc. (ATHX) Stock” was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://dakotafinancialnews.com/2019/03/20/william-lehmann-jr-sells-15000-shares-of-athersys-inc-athx-stock.html.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also: Hedge Funds – How They Work For Investors

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.